|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
C4 Therapeutics, Inc. (CCCC) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
49,280,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile C4 Therapeutics is a biopharmaceutical company engaged in the development of novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Co.'s primary product candidate is CFT7455, an orally bioavailable degrader targeting IKZF1/3 for multiple myeloma, peripheral T-cell lymphoma, and mantle cell lymphoma. Co. is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid malignancies; and BRAF V600E and RET programs for genetically defined resistant solid tumors.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
5,667 |
| Total Buy Value |
$0 |
$0 |
$0 |
$31,735 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Salter Malcolm |
Director |
– • – |
2021-10-04 |
4 |
A |
$44.99 |
$13,497 |
D/D |
300 |
13,217 |
|
- |
|
| Cohen Alain J |
Director |
– • – |
2021-10-04 |
4 |
A |
$44.99 |
$9,988 |
D/D |
222 |
222 |
|
- |
|
| Anderson Kenneth Carl |
Director |
– • – |
2021-10-04 |
4 |
A |
$44.99 |
$8,728 |
D/D |
194 |
85,560 |
|
- |
|
| Crystal Adam |
Chief Medical Officer |
• – – |
2021-10-01 |
4 |
AS |
$44.25 |
$681,438 |
D/D |
(15,000) |
0 |
|
- |
|
| Crystal Adam |
Chief Medical Officer |
• – – |
2021-10-01 |
4 |
OE |
$4.98 |
$74,700 |
D/D |
15,000 |
15,000 |
|
- |
|
| Prokupets Elena |
Director |
– • – |
2021-09-27 |
4 |
AS |
$50.04 |
$92,573 |
I/I |
(1,850) |
503,126 |
|
- |
|
| Prokupets Elena |
Director |
– • – |
2021-09-24 |
4 |
AS |
$50.10 |
$151,065 |
I/I |
(3,015) |
504,437 |
|
- |
|
| Prokupets Elena |
Director |
– • – |
2021-09-23 |
4 |
AS |
$50.35 |
$966,772 |
I/I |
(19,180) |
506,552 |
|
- |
|
| Prokupets Elena |
Director |
– • – |
2021-09-22 |
4 |
AS |
$50.09 |
$528,415 |
I/I |
(10,548) |
519,360 |
|
- |
|
| Prokupets Elena |
Director |
– • – |
2021-09-21 |
4 |
AS |
$50.13 |
$517,461 |
I/I |
(10,321) |
526,364 |
|
- |
|
| Prokupets Elena |
Director |
– • – |
2021-09-17 |
4 |
AS |
$50.04 |
$542,495 |
I/I |
(10,840) |
531,697 |
|
- |
|
| Salter Malcolm |
Director |
– • – |
2021-09-17 |
4 |
AS |
$49.89 |
$37,667 |
D/D |
(755) |
12,917 |
|
- |
|
| Prokupets Elena |
Director |
– • – |
2021-09-16 |
4 |
AS |
$48.62 |
$1,289,285 |
I/I |
(26,499) |
510,385 |
|
- |
|
| Prokupets Elena |
Director |
– • – |
2021-09-15 |
4 |
AS |
$48.71 |
$2,645,894 |
I/I |
(54,193) |
563,538 |
|
- |
|
| Prokupets Elena |
Director |
– • – |
2021-09-14 |
4 |
AS |
$50.01 |
$49,217 |
I/I |
(984) |
587,731 |
|
- |
|
| Prokupets Elena |
Director |
– • – |
2021-09-13 |
4 |
AS |
$50.07 |
$333,474 |
I/I |
(6,660) |
588,223 |
|
- |
|
| Siegel Jolie |
Chief Legal Officer |
• – – |
2021-09-10 |
4 |
AS |
$50.00 |
$625,000 |
D/D |
(12,500) |
0 |
|
- |
|
| Siegel Jolie |
Chief Legal Officer |
• – – |
2021-09-10 |
4 |
OE |
$4.98 |
$62,250 |
D/D |
12,500 |
12,500 |
|
- |
|
| Prokupets Elena |
Director |
– • – |
2021-09-10 |
4 |
AS |
$50.00 |
$127,511 |
I/I |
(2,550) |
591,553 |
|
- |
|
| Salter Malcolm |
Director |
– • – |
2021-08-20 |
4 |
AS |
$40.73 |
$30,751 |
D/D |
(755) |
13,672 |
|
- |
|
| Fisher Stewart |
Chief Scientific Officer |
• – – |
2021-08-03 |
4 |
AS |
$45.01 |
$767,812 |
D/D |
(17,057) |
22,744 |
|
- |
|
| Prokupets Elena |
Director |
– • – |
2021-08-03 |
4 |
AS |
$45.16 |
$650,587 |
I/I |
(14,407) |
88,574 |
|
- |
|
| Prokupets Elena |
Director |
– • – |
2021-08-02 |
4 |
AS |
$45.01 |
$191,606 |
I/I |
(4,257) |
102,981 |
|
- |
|
| Fisher Stewart |
Chief Scientific Officer |
• – – |
2021-08-02 |
4 |
AS |
$45.00 |
$814,756 |
D/D |
(18,104) |
39,801 |
|
- |
|
| Prokupets Elena |
Director |
– • – |
2021-07-29 |
4 |
AS |
$45.00 |
$510,168 |
I/I |
(11,336) |
107,238 |
|
- |
|
166 Records found
|
|
Page 5 of 7 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
